QUEST Research Institute | Farmington Hills, MI
Status and phase
Conditions
Treatments
About
This is a Phase 2a study to assess the safety and tolerability of TPN-101 patients with PSP.
Full description
This is a Phase 2a multi-center, randomized, double-blind, placebo-controlled parallel-group, 4-arm study with an open-label treatment phase in patients with PSP. This study includes a 6-week Screening Period, a 24-week Double-blind Treatment Period, a 24-week Open label Treatment Period, and a Follow-up Visit 4 weeks post treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Patients must not meet any of the following criteria:
Primary purpose
Allocation
Interventional model
Masking
40 participants in 4 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal